Pfizer will not apply for emergency use authorization of its coronavirus disease 2019 (COVID-19) vaccine until at least mid-November; infectious disease experts warn of a potential third wave of COVID-19; rates of major depression increased among millennials.
This past Friday, Albert Bourla, PhD, CEO of Pfizer, said that the company would not apply for emergency use authorization (EUA) of its vaccine candidate against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), before the third week of November, which would rule out the possibility of a vaccine ready before Election Day on November 3. The New York Times reports that Bourla says that although preliminary numbers could be collected by the end of October on the vaccine’s efficacy, it would still take at least until mid-November to collect safety and manufacturing data.
According to CNBC, infectious disease experts have warned that the dangerously high number of COVID-19 cases currently in the United States could signal a potentially significant third wave as cases may push even higher ahead of the flu season. As of this past Friday, US COVID-19 cases have grown by 5% in 38 states, with the nation now averaging approximately 55,000 new cases every day, marking a 16% increase compared with a week ago.
According to an analysis by the Blue Cross Blue Shield Association (BCBSA), a 12% increase was found in rates of major depression among a cohort of millennials from 2017 to 2018, with increased rates of alcohol use disorder (7%), tobacco use disorder (5%), and substance use disorder (5%) also noted within the time span. Reported by FierceHealthcare, the report additionally detailed the worsening impact of the pandemic on these trends. Based on survey data conducted by the BCBSA in September of this year, 92% of millennials said the pandemic is having a negative effect on their mental health, 34% reported increased alcohol consumption, and 20% reported an increase in smoking.
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More